busulfan + PEG-ADA ERT
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ADA-SCID
Conditions
ADA-SCID
Trial Timeline
Aug 2, 2013 → Aug 27, 2018
NCT ID
NCT01852071About busulfan + PEG-ADA ERT
busulfan + PEG-ADA ERT is a phase 1/2 stage product being developed by Allergy Therapeutics for ADA-SCID. The current trial status is completed. This product is registered under clinical trial identifier NCT01852071. Target conditions include ADA-SCID.
Hype Score Breakdown
Clinical
9
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01852071 | Phase 1/2 | Completed |